SEARCH RESULT

Total Matching Records found : 326

Dinesh Thakur, an ex-Ranbaxy employee who blew the whistle on the company, interviewed by The Economic Times

-The Economic Times Indian pharmaceutical company Ranbaxy recently paid $500 million to the US government to settle civil and criminal charges for making fraudulent statements to the US FDA and selling adulterated drugs in the US. Dinesh Thakur, an ex-Ranbaxy employee who blew the whistle on the company, talks to ET about the five-year long investigation and the future of generic drug companies in the US. Edited Excerpts: * You think you...

More »

A deception most foul-Narayan Lakshman

-The Hindu   Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...

More »

USFDA scrutiny: Will pharma majors like Ranbaxy, Wockhardt be affected in long-term? -G Seetharaman

-The Economic Times Japanese companies do not mind erring on the side of caution. They are known to think longer and harder than their counterparts in other countries about big decisions, especially when it comes to entering a new market or acquiring a foreign company. But Japan's third biggest drugmaker Daiichi Sankyo would now wish it had spent more time doing due diligence on Ranbaxy Labs, in which it bought a...

More »

Ranbaxy case may take a toll on other Indian drug makers

-The Business Standard The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian Pharmaceutical Companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals. Last week, Ranbaxy had agreed to...

More »

New bulk drug export norms to comply with EU standards

-The Hindu The Commerce and Industry Ministry, on Thursday, issued new guidelines for pharmaceutical makers to comply with the European Union (EU) Good Manufacturing Practice (GMP) standards. In a statement issued here, the Ministry says such a move will give a boost to pharma exports from India. "India has demonstrated its keenness to meet international requirements for exports of pharmaceutical products yet again by taking timely action for complying with the new...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close